These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22851409)

  • 21. Feasibility of semiquantitative liver perfusion assessment by ferucarbotran bolus injection in double-contrast hepatic MRI.
    Fischer MA; Donati OF; Reiner CS; Hunziker R; Nanz D; Boss A
    J Magn Reson Imaging; 2012 Jul; 36(1):168-76. PubMed ID: 22334302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration.
    Golfieri R; Grazioli L; Orlando E; Dormi A; Lucidi V; Corcioni B; Dettori E; Romanini L; Renzulli M
    J Magn Reson Imaging; 2012 Sep; 36(3):648-57. PubMed ID: 22592930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic accuracy of intracellular uptake rates calculated using dynamic Gd-EOB-DTPA-enhanced MRI for hepatic fibrosis stage.
    Juluru K; Talal AH; Yantiss RK; Spincemaille P; Weidman EK; Giambrone AE; Jalili S; Sourbron SP; Dyke JP
    J Magn Reson Imaging; 2017 Apr; 45(4):1177-1185. PubMed ID: 27527820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spleen size measured on enhanced MRI for quantitatively staging liver fibrosis in minipigs.
    Chen XL; Chen TW; Li ZL; Zhang XM; Chen N; Zeng NL; Li H; Tang HJ; Pu Y; Li CP
    J Magn Reson Imaging; 2013 Sep; 38(3):540-7. PubMed ID: 23349034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocellular carcinoma in cirrhotic liver: double-contrast-enhanced, high-resolution 3.0T-MR imaging with pathologic correlation.
    Yoo HJ; Lee JM; Lee MW; Kim SJ; Lee JY; Han JK; Choi BI
    Invest Radiol; 2008 Jul; 43(7):538-46. PubMed ID: 18580337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepato-specific contrast-enhanced sequences in staging liver fibrosis--a multiparametric approach.
    Feier D; Balassy C; Bastati N; Fragner R; Wrba F; Ba-Ssalamah A
    Eur Radiol; 2016 Feb; 26(2):539-46. PubMed ID: 25991488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High spatial resolution, respiratory-gated, t1-weighted magnetic resonance imaging of the liver and the biliary tract during the hepatobiliary phase of gadoxetic Acid-enhanced magnetic resonance imaging.
    Lee ES; Lee JM; Yu MH; Shin CI; Woo HS; Joo I; Stemmer A; Han JK; Choi BI
    J Comput Assist Tomogr; 2014; 38(3):360-6. PubMed ID: 24681858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of magnetic resonance elastography and gadoxetate disodium-enhanced magnetic resonance imaging for the evaluation of hepatic fibrosis.
    Choi YR; Lee JM; Yoon JH; Han JK; Choi BI
    Invest Radiol; 2013 Aug; 48(8):607-13. PubMed ID: 23538889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative assessment of hepatic fibrosis in chronic hepatitis B and C: T1 mapping on Gd-EOB-DTPA-enhanced liver magnetic resonance imaging.
    Pan S; Wang XQ; Guo QY
    World J Gastroenterol; 2018 May; 24(18):2024-2035. PubMed ID: 29760545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis.
    Keller S; Aigner A; Zenouzi R; Kim AC; Meijer A; Weidemann SA; Krech T; Lohse AW; Adam G; Schramm C; Yamamura J
    PLoS One; 2018; 13(3):e0193929. PubMed ID: 29513767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis.
    Hanna RF; Kased N; Kwan SW; Gamst AC; Santosa AC; Hassanein T; Sirlin CB
    AJR Am J Roentgenol; 2008 Jan; 190(1):47-57. PubMed ID: 18094293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computer-aided diagnosis of hepatic fibrosis: preliminary evaluation of MRI texture analysis using the finite difference method and an artificial neural network.
    Kato H; Kanematsu M; Zhang X; Saio M; Kondo H; Goshima S; Fujita H
    AJR Am J Roentgenol; 2007 Jul; 189(1):117-22. PubMed ID: 17579160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations.
    Watanabe H; Kanematsu M; Goshima S; Kondo H; Onozuka M; Moriyama N; Bae KT
    Radiology; 2011 Apr; 259(1):142-50. PubMed ID: 21248234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Staging liver fibrosis in chronic hepatitis B with T
    Yang L; Ding Y; Rao S; Chen C; Wu L; Sheng R; Fu C; Zeng M
    J Magn Reson Imaging; 2017 Apr; 45(4):1186-1194. PubMed ID: 27563840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study.
    Oto A; Fan X; Mustafi D; Jansen SA; Karczmar GS; Rubin DT; Kayhan A
    Acad Radiol; 2009 Oct; 16(10):1223-30. PubMed ID: 19524458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does injection flow rate have an impact on arterial phase image degradation in liver MRI? A comparison of gadoxetic acid versus gadobutrol.
    Cohen-Hallaleh V; Guo L; Hosseini-Nik H; Razaghi Kashani N; Menezes R; Jhaveri K
    Clin Radiol; 2017 Nov; 72(11):994.e1-994.e8. PubMed ID: 28673445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double contrast-enhanced MRI of viral hepatitis-induced cirrhosis: correlation of gross morphological signs with hepatic fibrosis.
    Yu JS; Shim JH; Chung JJ; Kim JH; Kim KW
    Br J Radiol; 2010 Mar; 83(987):212-7. PubMed ID: 19505965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3D-liver perfusion MRI with the MS-325 blood pool agent: a noninvasive protocol to asses liver fibrosis.
    Leporq B; Dumortier J; Pilleul F; Beuf O
    J Magn Reson Imaging; 2012 Jun; 35(6):1380-7. PubMed ID: 22281698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.